CTKB vs VRTX · rev $200.5M vs P/E 30, rev $12.00B
Cytek Biosciences Inc (CTKB) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Cytek Biosciences Inc (CTKB) is a medical devices company listed on US.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
Latest reported CTKB revenue for 2024-12-31 was $200.5M. Net income was -$6.0M. Revenue was up 3.9% from 2023-12-31 to 2024-12-31. CTKB currently screens at market cap $421.8M.
Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
CTKB currently screens at market cap $421.8M. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the CTKB and VRTX stock pages for the full models.
Not investment advice.